Table 1.
Neutrals | Inflammitants | Irritants | Exfoliants (may have low vesicant potential) | Vesicants |
Asparaginase Bevacizumab bleomycin Bortezomib cetuximab, Cyclophosphamide | Bortezomib | Bendamustine | Aclacinomycin cisplatin Docetaxel liposomal Doxorubicin mitoxantrone Oxaliplatin paclitaxel | Actinomycin D |
Cytarabine eribulin Fludarabine gemcitabine Ifosfamide | 5-Fluorouracil methotrexate raltitrexed | Bleomycin | Dactinomycin daunorubicin Doxorubicin epirubicin Idarubicin mitomycin C Vinblastine vindesine | |
Melphalan rituximab | Carboplatin dexrasoxane | Vincristine vinorelbine | ||
Trastuzumab | Etoposide | |||
Teniposide | ||||
Topotecan |